Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$8.76
-0.07-0.79%
At close: -
$8.80
0.040.46%
After Hours: 1:09 PM EDT
Comments
Loading...
KalVista Pharma (NASDAQ:KALV) Stock, Analyst Ratings, Price Targets, Forecasts
KalVista Pharmaceuticals Inc has a consensus price target of $26.17 based on the ratings of 8 analysts. The high is $35 issued by Jones Trading on September 27, 2024. The low is $20 issued by HC Wainwright & Co. on December 6, 2024. The 3 most-recent analyst ratings were released by B of A Securities, HC Wainwright & Co., and Needham on December 18, 2024, December 6, 2024, and December 5, 2024, respectively. With an average price target of $23.33 between B of A Securities, HC Wainwright & Co., and Needham, there's an implied 165.15% upside for KalVista Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
HC Wainwright & Co.
Needham
Jones Trading
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for KalVista Pharma
Data brought to you by Benzinga APIs
FAQ
What is the target price for KalVista Pharma (KALV) stock?
The latest price target for KalVista Pharma (NASDAQ:KALV) was reported by B of A Securities on December 18, 2024. The analyst firm set a price target for $22.00 expecting KALV to rise to within 12 months (a possible 150.00% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for KalVista Pharma (KALV)?
The latest analyst rating for KalVista Pharma (NASDAQ:KALV) was provided by B of A Securities, and KalVista Pharma initiated their buy rating.
When was the last upgrade for KalVista Pharma (KALV)?
There is no last upgrade for KalVista Pharma
When was the last downgrade for KalVista Pharma (KALV)?
There is no last downgrade for KalVista Pharma.
When is the next analyst rating going to be posted or updated for KalVista Pharma (KALV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KalVista Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KalVista Pharma was filed on December 18, 2024 so you should expect the next rating to be made available sometime around December 18, 2025.
Is the Analyst Rating KalVista Pharma (KALV) correct?
While ratings are subjective and will change, the latest KalVista Pharma (KALV) rating was a initiated with a price target of $0.00 to $22.00. The current price KalVista Pharma (KALV) is trading at is $8.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.